Last reviewed · How we verify
Anti-EGFR-Containing Regimen
Anti-EGFR-Containing Regimen is a EGFR inhibitor Small molecule drug developed by Hoffmann-La Roche. It is currently in Phase 2 development for Non-small cell lung cancer.
Inhibits the epidermal growth factor receptor (EGFR)
Inhibits the epidermal growth factor receptor (EGFR) Used for Non-small cell lung cancer.
At a glance
| Generic name | Anti-EGFR-Containing Regimen |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Drug class | EGFR inhibitor |
| Target | EGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
This inhibition prevents the proliferation of cancer cells that overexpress EGFR.
Approved indications
- Non-small cell lung cancer
Common side effects
- Rash
- Diarrhea
- Fatigue
Key clinical trials
- A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. (PHASE1)
- Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis (PHASE1, PHASE2)
- A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. (PHASE1)
- Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer (PHASE3)
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (PHASE1, PHASE2)
- Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors (PHASE1)
- MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01) (PHASE1, PHASE2)
- BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-EGFR-Containing Regimen CI brief — competitive landscape report
- Anti-EGFR-Containing Regimen updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI
Frequently asked questions about Anti-EGFR-Containing Regimen
What is Anti-EGFR-Containing Regimen?
Anti-EGFR-Containing Regimen is a EGFR inhibitor drug developed by Hoffmann-La Roche, indicated for Non-small cell lung cancer.
How does Anti-EGFR-Containing Regimen work?
Inhibits the epidermal growth factor receptor (EGFR)
What is Anti-EGFR-Containing Regimen used for?
Anti-EGFR-Containing Regimen is indicated for Non-small cell lung cancer.
Who makes Anti-EGFR-Containing Regimen?
Anti-EGFR-Containing Regimen is developed by Hoffmann-La Roche (see full Hoffmann-La Roche pipeline at /company/roche).
What drug class is Anti-EGFR-Containing Regimen in?
Anti-EGFR-Containing Regimen belongs to the EGFR inhibitor class. See all EGFR inhibitor drugs at /class/egfr-inhibitor.
What development phase is Anti-EGFR-Containing Regimen in?
Anti-EGFR-Containing Regimen is in Phase 2.
What are the side effects of Anti-EGFR-Containing Regimen?
Common side effects of Anti-EGFR-Containing Regimen include Rash, Diarrhea, Fatigue.
What does Anti-EGFR-Containing Regimen target?
Anti-EGFR-Containing Regimen targets EGFR and is a EGFR inhibitor.
Related
- Drug class: All EGFR inhibitor drugs
- Target: All drugs targeting EGFR
- Manufacturer: Hoffmann-La Roche — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Non-small cell lung cancer
- Compare: Anti-EGFR-Containing Regimen vs similar drugs
- Pricing: Anti-EGFR-Containing Regimen cost, discount & access